References
- Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apo cells. Nature 1997; 390(6658)350–351
- Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apo cells. Nature 2000; 405(6782)85–90
- Park D, Tosello-Trampont AC, Elliott MR, Lu M, Haney LB, Ma Z, et al. BAI1 is an engulfment receptor for apo cells upstream of the ELMO/Dock180/Rac module. Nature 2007; 450(7168)430–434
- Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a phosphatidylserine receptor. Nature 2007; 450(7168)435–439
- Wu Y, Tibrewal N, Birge RB. Phosphatidylserine recognition by phagocytes: A view to a kill. Trends Cell Biol 2006; 16(4)189–197
- Païdassi H, Tacnet-Delorme P, Garlatti V, Darnault C, Ghebrehiwet B, Gaboriaud C, et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apo cell recognition. J Immunol 2008; 180(4)2329–2338
- Lorenz HM, Grünke M, Hieronymus T, Winkler S, Blank N, Rascu A, et al. Hyporesponsiveness to gamma c-chain cytokines in activated lymphocytes from patients with SLE leads to accelerated apo. Eur J Immunol 2002; 32(5)1253–1263
- Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, et al. Impaired uptake of apo cells into tingible body macrophages in germinal centers of patients with SLE. Arthritis Rheum 2002; 46(1)191–201
- Gaipl US, Beyer TD, Heyder P, Kuenkele S, Böttcher A, Voll RE, et al. Cooperation between C1q and DNase I in the clearance of nec cell-derived chromatin. Arthritis Rheum 2004; 50(2)640–649
- Gabler C, Blank N, Hieronymus T, Schiller M, Berden JH, Kalden JR, et al. Extranuclear detection of histones and Nucs in activated human lymphoblasts as an early event in apo. Ann Rheum Dis 2004; 63(9)1135–1144
- Schiller M, Bekeredjian-Ding I, Heyder P, Blank N, Ho AD, Lorenz HM. Autoantigens are translocated into small apo bodies during early stages of apo. Cell Death Differ 2008; 15(1)183–191
- Dall'Era MC, Cardarelli PM, Preston BT, Witte A, Davis JC, Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64(12)1692–1697
- Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with SLE. Arthritis Rheum 2006; 54(9)2951–2962
- Rahman AH, Eisenberg RA. The role of toll-like receptors in SLE. Springer Semin Immun 2006; 28: 131–143
- Lövgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Rönnblom L. Induction of interferon-alpha by immune complexes or liposomes containing SLE autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006; 54(6)1917–1927
- Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apo cell material by MoMa from patients with SLE. Arthritis Rheum 1998; 41(7)1241–1250
- Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apo cells by human macrophages. J Exp Med 1998; 188(12)2313–2320
- Distler JH, Huber LC, Hueber AJ, Reich CF, 3rd, Gay S, Distler O, et al. The release of microparticles by apo cells and their effects on macrophages. Apoptosis 2005; 10(4)731–741
- Cocca BA, Cline AM, Radic MZ. Blebs and apo bodies are B-cell autoantigens. J Immunol Jul 2002; 169(1)159–166
- Heyder P, Bekeredjian-Ding I, Parcina M, Blank N, Ho AD, Herrmann M, et al. Purified apo bodies stimulate PDC to produce IFN-alpha. Autoimmunity 2007; 40: 331–332